PRTT Protect Pharmaceutical Corp

(UPDATE) The game changing acquisition announced by Protect Pharmaceutical Corporation.

(UPDATE) The game changing acquisition announced by Protect Pharmaceutical Corporation.

After many months of strategic planning and development, the two companies are ready to announce the details of their upcoming acquisition deal.

Minsk, Belarus., June 23, 2022 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corporation, Inc. “OTC:(PRTT)” will enter into a share exchange agreement with СJSC “Inaiapp” (a leading blockchain solutions provider in EU region) in order to secure its strategic goals for the web 3.0 market. The agreement is to acquire 100% of the outstanding shares of Inaiapp. Inaiapp has an extremely strong development and management team that will bring instant significant value to PRTT.

The deal will drive PRTT’s position as an emerging tech innovation company and allow the consolidation of financial flows required to develop and launch its premier products ( and others) according to company intentions and goals.

“We not only point out the obvious value, that Inaiapp will bring to PRTT, but also the impact, that public trading company could create with Inaiapp’s assets”, says Nick Greb President of Protect Pharmaceutical Corporation, Inc.

Established in 2014, Inaiapp has 8 years of blockchain development experience, helping businesses grow. The company brings high end business automation and DLT-based tools, offering exceptional speeds, constant data integrity, high security and scalability to its clients.

About PRTT

Protect Pharmaceutical Corporation is a full-cycle software development and delivery company that produces, releases, and supports digital products for the business-to-business and business-to-consumer markets. The company’s expertise lies in custom software development and consulting services in Business automation, Artificial Intelligence, Machine Learning, Data Science, Big Data, Image recognition, Blockchain development, and cloud services. Its domain focus includes Supply chain, Logistics, Healthcare, Finance, Real estate, Legal, Insurance, Advertising, and more.

For more information contact:

Protect Pharmaceutical Corporation, Inc.

(347) 692 8942



EN
23/06/2022

Underlying

PRTTProtect Pharmaceutical Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Protect Pharmaceutical Corp

 PRESS RELEASE
Free
PRTT Protect Pharmac...

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 29, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. We wanted to update shareholders in regards to the progress on our PCAOB Audit. We had a small delay that originated from the auditor needing physical access to a secure facility that houses customs products. We believe the delay will be minimal and are still on track to finalize our audit within the next week to two weeks. We apologize for the unforeseen dela...

December 29, 2023 1 EN
 PRESS RELEASE
Free
PRTT Protect Pharmac...

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pha...

Ali Yildiz December 22, 2023 Letter to the Shareholders of Protect Pharmaceutical Corp. Istanbul, Turkey, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. As we stated last week we are in the final stages of our PCAOB audit and expect its completion very soon. We have now responded to the open items to the auditor. We expect to receive the finalized audit report very soon and feel we can still meet our goal of completion before year end. As we end the year we are optimistic and believe that the company has accom...

December 22, 2023 1 EN
 PRESS RELEASE
Free
PRTT Protect Pharmac...

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As CEO of PRTT I wanted to update shareholders on current progress within the company. We posted our largest quarter for revenues for the second consecutive quarter. Our growth strategy is working and we recently announced the acquisition of Bosfor Export. This is one of several acquisition targets and we plan to continue to grow and expand not only our curr...

December 15, 2023 1 EN
 PRESS RELEASE
Free
PRTT Protect Pharmac...

Protect Pharmaceutical Corp. Acquires Bosfor Export

Protect Pharmaceutical Corp. Acquires Bosfor Export Istanbul, Turkey, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export. This strategic move has been financed through the issuance of 2,000,000 restricted shares, representing 100% ownership of Bosfor Export. Bosfor Export, known for its robust fruit wholesaling operations in Istanbul, currently achieves an annual revenue of approximately $28 million USD. With this acquisition, PRTT's management is optimistic about significantly increasing revenues by leveragi...

November 24, 2023 1 EN
 PRESS RELEASE
Free
PRTT Protect Pharmac...

Protect Pharmaceutical Corp. CEO Provides Shareholder Update

Protect Pharmaceutical Corp. CEO Provides Shareholder Update Istanbul, Turkey, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Protect Pharmaceutical Corp. CEO Ali Yildiz Provides Shareholder Update. As we enter the 4th quarter we feel the company has entered a very pivotal time in our growth strategy. We posted our largest quarter for revenues in the second quarter of 2023 and our expansion goals and strategies are progressing very nicely. For the 6 months ending June 30, 2023 we had 62 million dollars in revenue with an operating profit of over 18 million...

September 26, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch